Masimo (NASDAQ:MASI) Releases Q4 2024 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its fourth quarter 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 1.350-1.500 for the period, compared to the consensus EPS estimate of 1.410. The company issued revenue guidance of $581.0 million-$611.0 million, compared to the consensus revenue estimate of $607.4 million. Masimo also updated its FY24 guidance to $3.95-$4.10 EPS.

Masimo Price Performance

Shares of Masimo stock traded up $16.07 on Wednesday, hitting $167.63. 2,121,364 shares of the company were exchanged, compared to its average volume of 574,318. Masimo has a 1-year low of $75.36 and a 1-year high of $173.90. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of 114.03 and a beta of 0.97. The company has a 50-day moving average price of $131.74 and a 200 day moving average price of $125.64.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. As a group, sell-side analysts predict that Masimo will post 3.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

MASI has been the topic of several analyst reports. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler raised their price objective on shares of Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday. Wells Fargo & Company boosted their target price on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target on the stock in a research note on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $152.57.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.